Lilja H - Search Results

1

Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.

Mikropoulos C, Selkirk CGH, Saya S, Bancroft E, Vertosick E, Dadaev T, Brendler C, Page E, Dias A, Evans DG, Rothwell J, Maehle L, Axcrona K, Richardson K, Eccles D, Jensen T, Osther PJ, van Asperen CJ, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Hart R, Glover W, Lam J, Taylor L, Salinas M, Feliubadaló L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Cook J, Rosario DJ, Buys SS, Conner T, Domchek S, Powers J, Ausems MG, Teixeira MR, Maia S, Izatt L, Schmutzler R, Rhiem K, Foulkes WD, Boshari T, Davidson R, Ruijs M, Helderman-van den Enden AT, Andrews L, Walker L, Snape K, Henderson A, Jobson I, Lindeman GJ, Liljegren A, Harris M, Adank MA, Kirk J, Taylor A, Susman R, Chen-Shtoyerman R, Pachter N, Spigelman A, Side L, Zgajnar J, Mora J, Brewer C, Gadea N, Brady AF, Gallagher D, van Os T, Donaldson A, Stefansdottir V, Barwell J, James PA, Murphy D, Friedman E, Nicolai N, Greenhalgh L, Obeid E, Murthy V, Copakova L, McGrath J, Teo SH, Strom S, Kast K, Leongamornlert DA, Chamberlain A, Pope J, Newlin AC, Aaronson N, Ardern-Jones A, Bangma C, Castro E, Dearnaley D, Eyfjord J, Falconer A, Foster CS, Gronberg H, Hamdy FC, Johannsson O, Khoo V,… See abstract for full author list ➔ Mikropoulos C, et al. Among authors: lilja h. Br J Cancer. 2018 Jan;118(2):266-276. doi: 10.1038/bjc.2017.429. Epub 2018 Jan 4. Br J Cancer. 2018. PMID: 29301143 Free PMC article.

2

Prostate specific antigen predominantly forms a complex with alpha 1-antichymotrypsin in blood. Implications for procedures to measure prostate specific antigen in serum.

Lilja H, Cockett AT, Abrahamsson PA. Lilja H, et al. Cancer. 1992 Jul 1;70(1 Suppl):230-4. doi: 10.1002/1097-0142(19920701)70:1+<230::aid-cncr2820701310>3.0.co;2-y. Cancer. 1992. PMID: 1376193 Review.

3

Molecular forms of serum prostate-specific antigen. The clinical value of percent free prostate-specific antigen.

Abrahamsson PA, Lilja H, Oesterling JE. Abrahamsson PA, et al. Among authors: lilja h. Urol Clin North Am. 1997 May;24(2):353-65. doi: 10.1016/s0094-0143(05)70382-7. Urol Clin North Am. 1997. PMID: 9126233 Review.

4

Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL.

Törnblom M, Norming U, Adolfsson J, Becker C, Abrahamsson PA, Lilja H, Gustafsson O. Törnblom M, et al. Among authors: lilja h. Urology. 1999 May;53(5):945-50. doi: 10.1016/s0090-4295(98)00640-2. Urology. 1999. PMID: 10223488

5

Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden.

Hugosson J, Aus G, Becker C, Carlsson S, Eriksson H, Lilja H, Lodding P, Tibblin G. Hugosson J, et al. Among authors: lilja h. BJU Int. 2000 Jun;85(9):1078-84. doi: 10.1046/j.1464-410x.2000.00679.x. BJU Int. 2000. PMID: 10848699

6

Variation in percentage-free prostate-specific antigen (PSA) with prostate volume, age and total PSA level.

Törnblom M, Norming U, Becker C, Lilja H, Gustafsson O. Törnblom M, et al. Among authors: lilja h. BJU Int. 2001 May;87(7):638-42. doi: 10.1046/j.1464-410x.2001.02143.x. BJU Int. 2001. PMID: 11350403

7

Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.

Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG, Pileblad E. Hugosson J, et al. Among authors: lilja h. J Urol. 2003 May;169(5):1720-3. doi: 10.1097/01.ju.0000061183.43229.2e. J Urol. 2003. PMID: 12686817

8

Lead time associated with screening for prostate cancer.

Törnblom M, Eriksson H, Franzén S, Gustafsson O, Lilja H, Norming U, Hugosson J. Törnblom M, et al. Among authors: lilja h. Int J Cancer. 2004 Jan 1;108(1):122-9. doi: 10.1002/ijc.11554. Int J Cancer. 2004. PMID: 14618626

9

Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden.

Hugosson J, Aus G, Bergdahl S, Fernlund P, Frösing R, Lodding P, Pihl CG, Lilja H. Hugosson J, et al. Among authors: lilja h. BJU Int. 2003 Dec;92 Suppl 2:39-43. doi: 10.1111/j.1465-5101.2003.04396.x. BJU Int. 2003. PMID: 14983953 Clinical Trial.

10

The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable.

Zackrisson B, Aus G, Bergdahl S, Lilja H, Lodding P, Pihl CG, Hugosson J. Zackrisson B, et al. Among authors: lilja h. J Urol. 2004 Apr;171(4):1500-3. doi: 10.1097/01.ju.0000118052.59597.83. J Urol. 2004. PMID: 15017207 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

578 results

Search Page

Filters